Key facts
- TL Genomics’s last known valuation is $13.0M (Aug 2020).
- It has raised $3.6M; the latest was Later Stage VC in Mar 2026.
- Notable investors include SMBC Venture Capital, Nissay Capital, DBJ Capital, Fukoku Bussan, Meinan Group's VC — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for TL Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for TL Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TL Genomics
Developer of a non-invasive prenatal diagnosis technology designed to isolate fetal nucleated red blood cells in maternal blood. The company's technology offers a non-invasive and definitive diagnosis of fetal chromosomal disorders that can be performed early in pregnancy and offers laminated microfluidic devices for massive cell fractionation, enabling healthcare providers to ensure the safe pregnancy of their patients.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2015
- Employees
- 10
- Website
- tlgenomics.com/
- Ownership
- Privately Held (backing)
TL Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TL Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TL Genomics in its N-PORT filings yet. We sweep new filings monthly.